Market Intelligence, Clinical Progress, and High-Purity Reagents for Dyslipidemia and Cardiovascular Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANGPTL8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANGPTL8/Betatrophin Recombinant Protein High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View ANGPTL8 Products |
| Complex Partner | ANGPTL3 Recombinant Protein For ANGPTL8-ANGPTL3 heterodimer formation assays. Critical for LPL inhibition studies. |
View ANGPTL3 Products |
| Family Control | ANGPTL4 Recombinant Protein Counter-screening for selectivity against related angiopoietin-like family members. |
View ANGPTL4 Products |
| Gene Delivery | ANGPTL8 Promise-ORF / Lentivirus Full-length ORF with secretion signal for stable cell line construction. Sequence Verified. |
View ANGPTL8 Products |
| Validator | ANGPTL8 siRNA Set For knockdown verification and specificity controls in hepatocyte models. |
View ANGPTL8 Products |
| Benchmark Ab | Anti-ANGPTL8 (Sequence-Defined Neutralizing Clone) Recombinant positive control for assay standardization. |
View ANGPTL8 Products |
| Metabolic Benchmark | PCSK9 Recombinant Protein & Antibody Comparative metabolic target for lipid pathway modulation studies. |
View PCSK9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Family Selectivity (ANGPTL3/4/8 cross-reactivity) | Purified ANGPTL3, ANGPTL4, ANGPTL8 proteins with distinct epitope regions verified by Mass Spec. >95% purity eliminates contaminant interference. |
| LPL Inhibition Mechanism Validation | Active ANGPTL8 protein (HEK293 expressed) for functional ELISA and LPL activity assays. Native glycosylation preserves conformational integrity. |
| Cross-species Preclinical Translation | Human/Mouse/Cyno ortholog proteins available with sequence verification for species-specific efficacy bridging studies. |
| False Positives in Binding Assays | Validated siRNA included for specificity checks; Endotoxin-controlled (<1EU/µg) to prevent LPS-mediated metabolic artifacts. |
| Lack of Neutralizing Controls | Research-grade benchmark antibody (sequence-defined) included for assay standardization. |
Live ANGPTL8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ANGPTL8 therapeutics is intensifying, with major players shifting focus from beta-cell proliferation hypotheses toward validated lipid-modulation mechanisms. As first-generation antibody therapies targeting the ANGPTL3/8 pathway enter Phase I/II, the next wave of R&D is targeting dual ANGPTL3/8 inhibition and tissue-specific delivery for severe hypertriglyceridemia. Human genetic and preclinical evidence strongly links ANGPTL8 loss-of-function to lower triglyceride levels, positioning it as an attractive node for dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes. While no late-stage clinical assets have been publicly disclosed, the approval of ANGPTL3-targeted therapies validates the broader angiopoietin-like pathway. Key therapeutic angles include monoclonal antibodies disrupting the ANGPTL8-ANGPTL3 complex, antisense oligonucleotides (ASO) for hepatic silencing, and bispecific constructs combining ANGPTL8 blockade with PCSK9 inhibition for comprehensive lipid management.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Regeneron, Novo Nordisk, Eli Lilly | Severe Hypertriglyceridemia, NASH | ANGPTL8-ANGPTL3 Heterodimer Disruption Assay (Need high-purity native proteins) |
| ASO/siRNA | Ionis Pharmaceuticals, Alnylam, Arrowhead | Familial Chylomicronemia Syndrome, Mixed Dyslipidemia | Hepatocyte Uptake & Knockdown Validation (Need Lentivirus and siRNA controls) |
| Bispecific | Emerging Biotechs | Combined Dyslipidemia, CVD with PCSK9 resistance | Dual Binding Epitope Mapping (Need ANGPTL8 + PCSK9 protein panel) |
| Peptide Inhibitors | Academic Consortiums | Type 2 Diabetes (Adjunct), Metabolic Syndrome | Sub-Q Stability & Bioavailability (Need high-concentration protein standards) |
Molecular Differentiation & Assay Strategy
Affinity & Complex Recognition
- Differentiation Need: ANGPTL8 functions primarily as a complex with ANGPTL3. Ideal antibodies must bind not only free ANGPTL8 but also the ANGPTL3/8 heterodimer with high affinity.
- Assay Strategy: SPR/BLI binding kinetics; competitive blocking of complex formation. TarMart provides HEK293-expressed, native glycosylated ANGPTL8 and ANGPTL3 proteins for accurate heterodimer reconstitution.
Delivery & Formulation
- Differentiation Need: Chronic metabolic disease requires subcutaneous injection. Formulations must remain stable and low-viscosity at high concentrations (>100 mg/mL).
- Assay Strategy: High-concentration aggregation testing (SEC-HPLC), thermal stability (DSF/Tm). TarMart's low-endotoxin, high-purity proteins support accurate formulation studies.
Mechanism of Action
- Differentiation Need: Drug must functionally rescue LPL activity by blocking ANGPTL3/8-mediated inhibition.
- Assay Strategy: In vitro LPL activity rescue assay. TarMart's tag-free or minimal-tag recombinant proteins minimize steric hindrance.
Safety & Selectivity
- Differentiation Need: Avoid cross-reactivity with ANGPTL4 (which can cause lymphatic/intestinal toxicity) and other family members.
- Assay Strategy: Cross-reactivity panel using purified ANGPTL family proteins. TarMart provides a complete panel of ANGPTL3, ANGPTL4, and ANGPTL8 proteins verified by mass spec.
Cross-species Translation
- Differentiation Need: Preclinical studies require mouse (efficacy) and cynomolgus monkey (toxicology) cross-reactivity.
- Assay Strategy: Binding assays with human, cyno, and mouse ortholog proteins. TarMart offers sequence-verified ortholog sets with >85% sequence identity.
Cross-sell Targets
- View ANGPTL3 Products: Obligate binding partner for LPL inhibition; essential for complex formation assays and combination therapy development.
- View ANGPTL4 Products: Compensatory LPL regulator; critical for selectivity counter-screening and resistance mechanism studies.
- View LPL Products: Downstream enzymatic target regulated by the ANGPTL3/8 complex; required for functional activity assays.
- View PCSK9 Products: Parallel metabolic target for combination therapy strategies in mixed dyslipidemia.